Hikma V. Amarin: It’s Not Just About Skinny Labels

Key Takeaways:

• In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, the Supreme Court reversed the Federal Circuit and held that a generic drug manufacturer’s FDA-compliant skinny label, combined with routine marketing statements describing its product as a “generic version” of the brand-name drug, does not state a claim for active inducement of patent infringement under 35 U.S.C. § 271(b).
• The Court, in a unanimous opinion delivered by Justice Jackson, held that, to survive a motion to dismiss, the patent owner must plausibly allege statements “designed to stimulate others” to infringe. Statements that merely “could stimulate others” are not sufficient.
• The decision explicitly rejects the Federal Circuit’s recent trend, as illustrated in GlaxoSmithKine LLC v. Teva Pharmaceuticals USA, Inc., 4 F.4^th 1320 (Fed. Cir. 2021), that allowed for a lower pleading standard based on whether a statement could be interpreted as encouraging infringement.
• The decision significantly strengthens the protections available to generic manufacturers that are marketing under the section viii “skinny-label” pathway, and it raises the pleading threshold for brand-name manufacturers seeking to assert induced infringement claims in the Hatch-Waxman context.
• The decision has implications beyond the Hatch-Waxman context. The analytical framework adopted by the Supreme Court should be considered as additional precedent in the area of induced infringement generally, following its prior indirect patent infringement decision in Global-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754 (2011), but also its prior indirect copyright infringement decisions, Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd., 545 U.S. 913 (2005), and Cox Communications, Inc. v. Sony Music Entertainment, 607 U.S. ___ (Mar. 25, 2026). This decision will apply, and should be considered, by all patent or copyright holders seeking to establish induced infringement.

Background

The Hatch-Waxman Act provides a pathway for generic drug manufacturers to enter the market without repeating extensive clinical trials required for new drug approval. When a brand-name drug is approved for multiple uses, some of which remain patented while others do not, a generic manufacturer may submit an abbreviated new drug application (“ANDA”) with a “section viii statement” carving out any approved uses that are still subject to patent protection and only seeking FDA approval to market the drug only for unpatented uses. A label, or prescribing information, that has had indications carved out is sometimes called a “skinny label,” because the still-patented methods of use are removed and the drug is described as having a narrower set of indications than the brand-name product. The Supreme Court has recognized that this mechanism was designed to permit generic competition for unpatented uses without being foreclosed by patents covering other indications. Caraco Pharmaceutical Labs. Ltd v. Novo Nordisk A/S, 566 U.S. 399 (2012). 

The Patent Act imposes liability for induced infringement under 35 U.S.C. § 271(b) on any party that “actively induces infringement” of a patent, such as by promoting a drug for a patented use. The Supreme Court has explained that inducement requires evidence of affirmative conduct undertaken with knowledge that the induced acts constitute patent infringement.

The tension between these two statutory frameworks has generated considerable uncertainty for both brand-name and generic pharmaceutical companies. Because a generic drug is, by definition, biologically equivalent to its brand-name counterpart (see Caraco), States require medical providers to prescribe and pharmacists to dispense the generic interchangeably with the brand-name drug, including for patented methods of use. The question presented was whether a generic manufacturer can be held liable for inducing that substitution when it complies with the skinny-label framework and makes routine commercial statements about its product.

The Hikma v. Amarin Dispute

Amarin Pharma, Inc. developed Vascepa, with the active ingredient icosapent ethyl. The FDA first approved Vascepa in 2012 for the treatment of severe hypertriglyceridemia (the “SH indication”). In 2019, the FDA approved Vascepa for a second, more common use: reducing cardiovascular risk in hypertriglyceridemia patients already taking statins (the “CV indication”). Amarin obtained method-of-use patents covering the CV indication, while other patents covering the SH indication were invalidated in earlier litigation between Amarin and Hikma.

Hikma Pharmaceuticals USA Inc., a generic drug manufacturer, filed an ANDA with a section viii statement carving out the patented CV indication. In 2020, the FDA approved Hikma’s generic version of Vascepa with a skinny label, limiting it to the unpatented SH indication.

After launch, Hikma issued press releases describing its generic as the “generic version” or “generic equivalent” of Vascepa, cited Vascepa’s total U.S. sales figures (attributable primarily to the CV indication), and listed its product on its website under the therapeutic category “Hypertriglyceridemia” — a term broad enough to encompass both patented and unpatented uses. Hikma also noted its rating allowing pharmacies to substitute its generic version for Vascepa prescriptions, but it included a disclaimer that its product was approved for fewer indications than Vascepa.

Amarin filed suit in the District of Delaware, alleging that the totality of Hikma’s statements across its skinny label, patient information leaflet, website, and press releases constituted active inducement to infringe its CV-indication patents. The District Court granted Hikma’s motion to dismiss for failure to state a claim.

The Federal Circuit reversed. It held that it was “at least plausible that a physician could read” the combination of Hikma’s label, website, and press releases “as an instruction or encouragement to prescribe [Hikma’s generic] for any of the approved uses of icosapent ethyl.”

The Supreme Court granted certiorari on January 16, 2026, on two questions: (1) whether allegations that a generic drugmaker calls its product a “generic version” and cites public information about the branded drug are enough to plead induced infringement when the label fully carves out the patented use; and (2) whether a complaint states a claim for induced infringement if it does not allege any instruction or statement by the defendant that encourages, or even mentions, the patented use.

The Court’s Analysis

Writing for a unanimous Court, Justice Jackson reversed the Federal Circuit and held that Amarin failed to state a claim for active inducement under § 271(b). The Court began by reaffirming the familiar Twombly/Iqbal pleading standard: to survive a motion to dismiss, a plaintiff must plead facts that allow the court to draw the reasonable inference that the defendant is liable, and to rule out “obvious alternative explanations” for the defendant’s conduct.

The Court then held that “inducement must involve the taking of affirmative,” as opposed to passive, “steps to bring about the desired result” of patent infringement, and that “ordinary acts incident to product distribution” are insufficient to support liability because courts must avoid “trenching on regular commerce.” To illustrate what “active steps” means in the inducement context, it referred not only its prior indirect patent infringement cases like Global-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754 (2011), but also its indirect copyright infringement cases, Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd., 545 U.S. 913 (2005), and Cox Communications, Inc. v. Sony Music Entertainment, 607 U.S. ___ (Mar. 26, 2026).

The Court drew a distinction that lies at the heart of its holding: “statements designed to stimulate others form a narrower category than statements that could stimulate others.” The central question to the analysis according to the Court, is whether the plaintiff plausibly alleged that the defendant “actively encouraged” infringing use — not merely whether a doctor could “plausibly read” the defendant’s statements as instructions to infringe. In a footnote, the Court took direct aim at the Federal Circuit’s recent approach to induced infringement, citing GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F. 4th 1320, 1336–1337 (CA Fed. 2021), as an example of a trend that had “increasingly trained its focus on whether the relevant statements could be read by medical providers as instructions to infringe.” The Court rejected that approach: “We reject that trend today, and hereby emphasize that the key question is whether a defendant actively encouraged infringement through its statements, not merely how others may understand those statements.”

The Court then applied these principles to the specific allegations in Amarin’s complaint:

Compliance with law and industry standards is not inducement. The Court found that several of Hikma’s statements had an “obvious alternative explanation”: compliance with law or standard industry practice. Hikma’s label retained information about a clinical study involving statin patients because, by statute, a generic label must be identical to the brand-name label except for the carved-out use. Describing a drug as a “generic version” or “generic equivalent” of the brand-name comparator is “normal industry practice,” and the Court declined to “put generic manufacturers between a rock and a hard place by turning adherence to the law and industry standards into building blocks for illegal conduct.”

Omissions cannot constitute active inducement. The Court held that Amarin could not rely on “mere omissions, inactions, or nonfeasance” to allege active inducement, citing Twitter, Inc. v. Taamneh, 598 U.S. 471, 489 (2023). With “a healthy stretch of the imagination, one might believe that some medical providers could read between the lines and draw improper conclusions” from the skinny label’s omission of the CV Limitation of Use and from Hikma’s failure to mention that its approved use was limited to the “far-lesser-known SH indication,” the decision stated. But the Court emphasized that it looks for affirmative “statements or actions” precisely to avoid “trenching on regular commerce” based on “such a contingent chain of events.” Otherwise, “ordinary merchants could become liable for any misuse of their goods and services, no matter how attenuated their relationship with the wrongdoer.”

Vague statements combined with speculation are insufficient. The Court found that “Amarin comes up short in resting the remainder of its inducement claim on ‘vague’ statements ‘combined with speculation about how [medical providers] may act’ in response to those statements.” It rejected Amarin’s argument that medical providers “would plausibly understand” Hikma’s patient information leaflet, website description, and press release sales figures as encouragement to prescribe for the patented CV indication. The website’s description of the therapeutic category as “hypertriglyceridemia” rather than “severe hypertriglyceridemia” was, the Court analogized, “generally akin to describing a drug for leukemia as a ‘cancer drug’” — “a broad category, not an instruction to prescribe the drug for a patented use treating a specific type of cancer.” As for the press releases’ inclusion of Vascepa’s total sales figures, the Court observed that a medical provider would have to look up and read investor-directed press releases, parse the financial data, and draw a “subtle encouragement” to prescribe for the CV indication — a chain of events the Court found “possib[le]” but not “plausible.”

Impact on Skinny Labels and Indirect Infringement

The decision carries significant implications for the pharmaceutical skinny-label context in which it arises. Two big takeaways emerge from the opinion.

First, carving an indication out of a label in compliance with FDA regulations, standing alone, will not support active inducement. The ruling provides considerable reassurance to generic manufacturers that the section viii skinny-label pathway remains a viable mechanism for market entry. All parties — including the Federal Circuit — agreed that “Hikma’s label, standing alone, does not induce infringement.” The question was whether non-label materials could change that conclusion. The Court’s answer, that FDA-compliant labeling combined with routine commercial statements cannot satisfy the “active steps” requirement, resolves a critical source of uncertainty. Before this decision, generic companies faced significant uncertainty about whether routine marketing communications describing their products as generics, referencing publicly available sales data, or using standard therapeutic category descriptions could expose them to induced infringement claims. Hikma itself had argued in its certiorari petition that under the Federal Circuit’s approach, “no skinny label is safe.” The Court’s holding effectively forecloses the theory that FDA-compliant labeling and standard commercial statements, standing alone or in combination, can satisfy the “active steps” requirement of §271(b).

Generic manufacturers should nonetheless continue to exercise care in their public-facing materials, and brand name manufacturers should continue to monitor such statements. The Court did not create blanket immunity from induced infringement liability or adopt any categorical exemption for the pharmaceutical industry. Rather, it addresses the pleading threshold — what a brand-name plaintiff must allege to survive a motion to dismiss. Because inducement can be achieved through “implicit encouragement” so long as it is “clear” and “affirmative,” a generic manufacturer whose communications are “designed to stimulate” prescribing for a patented indication could still face liability even without explicitly naming the patented use.

Second, inducement must be supported by affirmative acts to encourage infringement. The focus is on the actions of the alleged inducer, not on whether it is plausible that someone could construe an otherwise neutral statement as encouragement. This firms up, and raises, the standard relative to prior Federal Circuit precedent, and it does so in a manner that extends well beyond the skinny-label context (as the Court noted in rejected recent Federal Circuit jurisprudence). A brand-name manufacturer can no longer cobble together a plausible inducement theory from the generic’s label, routine press releases, and standard website. Instead, a complaint must allege that the generic manufacturer’s statements were designed to bring about infringing use — not merely that they could lead a physician to infringe. Future complaints will need to identify affirmative conduct that goes beyond the natural consequences of marketing a bioequivalent product under a lawful skinny label.

Brand-name companies that have invested heavily in post-approval clinical trials to secure expanded indications may find it more difficult to protect those investments through induced infringement litigation where the generic manufacturer has hewed to the skinny-label framework. This may prompt innovators to consider other strategies for protecting method-of-use patents, including more active monitoring of generic manufacturers’ promotional activities for affirmative statements that go beyond what the Court found permissible in Hikma.

Broader Implications Beyond Pharmaceuticals

Hikma is not just a skinny-label case. The Court’s reliance on its indirect copyright infringement precedents in Grokster and Cox Communications — alongside patent cases like Global-Tech — signals that the principles announced here apply to induced infringement doctrine generally, not merely within the Hatch-Waxman framework. The Court’s insistence that inducement requires affirmative conduct designed to encourage infringement, and its rejection of omission-based and speculation-based theories, will have implications for any industry in which a product has both patented and unpatented applications. From medical devices to software platforms, companies marketing dual-use products will need to evaluate how these standards apply to their own commercial communications. The heightened focus on the alleged inducer’s own conduct, rather than on how third parties might interpret otherwise neutral statements, represents a meaningful tightening of the induced infringement standard across all technology sectors.

Looking Ahead

The Hikma decision resolves a long-simmering conflict over the intersection of the Hatch-Waxman skinny-label pathway and induced infringement doctrine. Generic manufacturers should evaluate their existing marketing, investor communications, and website descriptions against the Court’s framework to confirm they remain within the bounds of compliance and standard practice. Brand-name manufacturers should reassess their enforcement strategies for method-of-use patents and consider whether any generic competitor’s conduct crosses the line the Court has now drawn between permissible commerce and actionable inducement. All patent and copyright holders should consider the decision carefully when assessing the plausibility of a claim of induced infringement.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.